Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells-Reference-Cited by-同舟云学术

Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells

Published:2023-01 Issue: Volume:642 Page:192-200
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Iwanaga Terunao,Chiba Tetsuhiro^ORCID,Nakamura Masato^ORCID,Kaneko Tatsuya,Ao Junjie,Qiang Na,Ma Yaojia,Zhang Jiaqi,Kogure Tadayoshi,Yumita Sae,Ishino Takamasa,Ogawa Keita,Kan Motoyasu^ORCID,Nakagawa Miyuki,Fujiwara Kisako,Fujita Naoto,Sakuma Takafumi,Kanzaki Hiroaki,Koroki Keisuke,Kusakabe Yuko^ORCID,Inoue Masanori,Kobayashi Kazufumi,Kanogawa Naoya,Kiyono Soichiro,Kondo Takayuki,Nakagawa Ryo,Ogasawara Sadahisa,Nakamoto Shingo,Muroyama Ryosuke,Kato Jun,Kanda Tatsuo,Maruyama Hitoshi^ORCID,Mimura Naoya,Honda Takuya^ORCID,Murayama Toshihiko,Nakamura Hiroyuki,Kato Naoya

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference40 articles.

1. Liver fibrosis–from bench to bedside;Friedman;J. Hepatol.,2003

2. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update;Elpek;World J. Gastroenterol.,2014

3. Liver cirrhosis;Tsochatzis;Lancet,2014

4. Treatment of patients with cirrhosis;Ge;N. Engl. J. Med.,2016

5. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies;D'Amico;J. Hepatol.,2006

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update;Current Issues in Molecular Biology;2023-05-11